Literature DB >> 8911711

Regulation and role of urokinase plasminogen activator in vascular remodelling.

V Tkachuk1, V Stepanova, P J Little, A Bobik.   

Abstract

1. Urokinase plasminogen activator (uPA) is produced and secreted by multiple vascular cell types, thus influencing the processes and the extent to which the vasculature is remodelled during the development of the intima or a neointima and during hypertrophy and angiogenesis. 2. Urokinase plasminogen activator mRNA expression is up- and down-regulated by growth factors, cytokines and steroids. Urokinase plasminogen activator is secreted as a single chain inactive form that may be proteolytically converted to active or inactive forms. Targeting of proteolytic activity may occur via focalized expression of uPA and its cell surface receptors (uPAR). Proteolytic activity is also controlled through the often co-ordinated expression of specific inhibitors. 3. A proteolytic cascade involving uPA provides its major role in tissue remodelling through the primary degradation of extracellular matrix and secondarily through the activation of transforming growth factor-beta or release from the matrix of basic fibroblast growth factor. In addition, uPA secreted by growth factor-stimulated vascular cells may contribute to the chemotactic and mitogenic responses ascribed to the growth factor and recent evidence strongly suggests that uPA has direct biological actions on vascular cells. 4. The cell surface binding of uPA via its growth factor-like domain to uPAR localizes and activates the protease, but may also initiate transmembrane signalling of biological responses, including migration/invasion and proliferation. As the uPAR lacks intracellular signalling domains, the signals may be transduced via interactions between uPA/uPAR and more classical signalling receptors. The mechanism by which uPA may be involved in cell signalling is yet to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911711     DOI: 10.1111/j.1440-1681.1996.tb01177.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  11 in total

1.  Vasculogenesis and Angiogenesis: Molecular and Cellular Controls. Part 2: Interactions between Cell and Extracellular Environment.

Authors:  N Kubis; B I Levy
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

2.  Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction.

Authors:  Teruo Inoue; Isao Yaguchi; Keiichi Mizoguchi; Toshihiko Uchida; Kan Takayanagi; Terumi Hayashi; Shigenori Morooka; Yutaka Eguchi
Journal:  Clin Cardiol       Date:  2003-03       Impact factor: 2.882

3.  Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

Authors:  A Poliakov; V Tkachuk; T Ovchinnikova; N Potapenko; S Bagryantsev; V Stepanova
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

4.  Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.

Authors:  D H Nguyen; A D Catling; D J Webb; M Sankovic; L A Walker; A V Somlyo; M J Weber; S L Gonias
Journal:  J Cell Biol       Date:  1999-07-12       Impact factor: 10.539

Review 5.  Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?

Authors:  G Christ; K Kostner; M Zehetgruber; B R Binder; D Gulba; K Huber
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

6.  Transcriptional activation of endothelial cells by TGFβ coincides with acute microvascular plasticity following focal spinal cord ischaemia/reperfusion injury.

Authors:  Richard L Benton; Melissa A Maddie; Toros A Dincman; Theo Hagg; Scott R Whittemore
Journal:  ASN Neuro       Date:  2009-08-26       Impact factor: 4.146

7.  Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.

Authors:  S P Oh; T Seki; K A Goss; T Imamura; Y Yi; P K Donahoe; L Li; K Miyazono; P ten Dijke; S Kim; E Li
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.

Authors:  Romaric Lacroix; Florence Sabatier; Agnès Mialhe; Agnès Basire; Ralph Pannell; Hélène Borghi; Stephane Robert; Edouard Lamy; Laurent Plawinski; Laurence Camoin-Jau; Victor Gurewich; Eduardo Angles-Cano; Françoise Dignat-George
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113

Review 9.  Angiogenesis and antiangiogenic strategies in pancreatic cancer.

Authors:  William E Fisher; David H Berger
Journal:  Int J Gastrointest Cancer       Date:  2003

10.  PLAUR polymorphisms and lung function in UK smokers.

Authors:  Ceri E Stewart; Ian P Hall; Stuart G Parker; Miriam F Moffat; Andrew J Wardlaw; Martin J Connolly; Charlotte Ruse; Ian Sayers
Journal:  BMC Med Genet       Date:  2009-10-31       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.